Desmin

Manufactured by Roche

Sourced in United States

Desmin is a protein that plays a key role in the structure and function of muscle cells. It is a type of intermediate filament that helps maintain the integrity and organization of the cytoskeleton within muscle cells. Desmin is commonly used as a biomarker in laboratory settings to identify and characterize muscle cells and related tissues.

Automatically generated - may contain errors

Lab products found in correlation

Benchmark ultra, by Roche (4 mentions) Benchmark xt, by Roche (3 mentions) Desmin, by Agilent Technologies (3 mentions) α sma, by Agilent Technologies (2 mentions) α sma, by Roche (2 mentions) Cyclin d1, by Thermo Fisher Scientific (2 mentions) H caldesmon, by Cell Marque (2 mentions) Cd163, by Roche (2 mentions) Ab76291, by Abcam (1 mentions) Sox10, by Cell Marque (1 mentions) Melan a, by Roche (1 mentions) Hmb45, by Agilent Technologies (1 mentions) M0634, by Agilent Technologies (1 mentions) Pan ck, by Roche (1 mentions) Alk d5f3, by Cell Signaling Technology (1 mentions) Pdgfr b, by Abcam (1 mentions) Vimentin, by Roche (1 mentions) Myogenin, by Cell Marque (1 mentions) Calretinin, by Roche (1 mentions) Ck5 6, by Roche (1 mentions)

Close spelling variants of this product

Desmin (clone DE-R-11; (2 citations)

14 protocols using desmin

Comprehensive Immunohistochemical Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry was performed on formalin-fixed paraffin-embedded tissue using 4 μm sections cut from paraffin blocks. Staining was performed using a fully automated system (Benchmark ULTRA, Ventana Medical Systems, Tuscon, AZ, USA) and the following antibodies were used: NTRK1 (Ab76291, 1:1,500, ABCAM), SOX10 (383A-75,1:50, CELL MARQUE), S100 (Z0311, 1:8,000, DAKO), H3 (9733, 1:100, CELL SIGNALING), CD34 (790-2927, VENTANA), SMA (VPS281, 1:50, VECTOR), Desmin (760-2513, VENTANA), Melan A (790-2990, VENTANA), STAT6 (SC-621, 1:2,500, SANTA CRUZ) and HMB45 (M0634, 1:100, DAKO).

Agaram N.P., Zhang L., Sung Y.S., Chen C.L., Chung C.T., Antonescu C.R, & Fletcher C.D. (2016). Recurrent NTRK1 Gene Fusions Define A Novel Subset Of Locally Aggressive Lipofibromatosis-Like Neural Tumors. The American journal of surgical pathology, 40(10), 1407-1416.

+ Open protocol

+ Expand

Histopathological Evaluation of Tumor

Check if the same lab product or an alternative is used in the 5 most similar protocols

For the histopathological evaluation, the tumour was tested using the streptavidin-biotin peroxidase complex method with antibodies against Caldesmon (Dako, Glostrup, Denmark), S100 (Dako), CD34 (Neomarkers, Fremont, CA), Desmin, EMA, and Pan-CK (all Ventana Medical Systems, Tucson, AZ).

Lohberger B., Stuendl N., Leithner A., Rinner B., Sauer S., Kashofer K, & Liegl-Atzwanger B. (2017). Establishment of a novel cellular model for myxofibrosarcoma heterogeneity. Scientific Reports, 7, 44700.

+ Open protocol

+ Expand

Immunohistochemical Analysis of FFPE Tumor Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serial 4-µm-thick sections were obtained from FFPE blocks representative of tumor tissue for immunohistochemical analysis. All reactions were performed using a BenchMark XT fully automated immunostainer (Ventana Medical Systems, Inc., Tucson, AZ, USA) and antibody incubation was for 8 h at 37°C. The following antibodies were used: Pan-cytokeratins (prediluted; cat. nos. 760–2521 and 790–4555 for clones AE1 and CAM5.2, respectively; Ventana Medical Systems, Inc.), smooth-muscle actin (prediluted; cat. no. 760–2833; Ventana Medical Systems, Inc.), desmin (prediluted; cat. no. 760–2513; Ventana Medical Systems, Inc.), p63 (prediluted; cat. no. 790–4509; Ventana Medical Systems, Inc.), CD21 (prediluted; cat. no. 760–4245; Ventana Medical Systems, Inc.), CD35 (prediluted; cat. no. 760–4439; Ventana Medical Systems, Inc.), HHV-8 (prediluted; cat. no. 760–4260; Ventana Medical Systems, Inc.), ALK (prediluted; cat. nos. 790–2918 and 790–4796 for clones ALK1 and D5F3, respectively; Ventana Medical Systems, Inc.), ALK (1:50 dilution; cat. no. NCL-L-ALK; Novocastra; Leica Microsystems, Inc., Buffalo Grove, IL, USA), S100 (prediluted; cat. no. 760–2523; Ventana Medical System, Inc.) and CD68 (prediluted; cat. no. 790–2931; Ventana Medical Systems, Inc.).

Muscarella L.A., Rossi G., Trombetta D., La Torre A., Di Candia L., Mengoli M.C., Sparaneo A., Fazio V.M, & Graziano P. (2016). A malignant inflammatory myofibroblastic tumor of the hypopharynx harboring the 3a/b variants of the EML4-ALK fusion gene. Oncology Letters, 13(2), 593-598.

+ Open protocol

+ Expand

Immunohistochemical Identification of Colorectal Myofibroblasts

Check if the same lab product or an alternative is used in the 5 most similar protocols

We selected the paraffin-embedded specimen which recognized three colorectal wall layers (SM, MP and SS), and the specimen also had the invasive lesion of the adenocarcninoma diagnosed by H&E staining. The selected paraffin embedded specimen was a representative block of each case, and we used 4-µm serial sections for immunohistochemistry. The sections were mounted on saline-coated glass slides. The antibodies used included α-smooth muscle actin (α-SMA) (1:100; clone 1A4) and desmin (1:100; clone D-33) (both from Dako, Glostrup, Denmark). Immunostaining for α-SMA and desmin was performed using the standard avidin-biotin-peroxidase complex method with an automated immunostainer (BenchMark XT; Ventana Medical System, Tucson, AZ, USA). The signature characteristic of the myofibroblast was the α-SMA-positive and desmin-negative pattern, whereas that of smooth muscle was the α-SMA- and desmin-positive pattern.

Takatsuna M., Morohashi S., Yoshizawa T., Hirai H., Haga T., Ota R., Saito K., Wu Y., Seino H., Aoyagi Y., Terai S, & Kijima H. (2016). Myofibroblast distribution is associated with invasive growth types of colorectal cancer. Oncology Reports, 36(6), 3154-3160.

+ Open protocol

+ Expand

Immunohistochemical Myofibroblast Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols

For immunohistochemical examination regarding the myofibroblast distribution in each case, the paraffin-embedded specimen which was described in 'Pathological analysis' was a representative specimen of each case, and we used serial 4-µm sections for the immunohistochemical analysis. The sections were mounted on saline-coated glass slides. The antibodies used included α-smooth muscle actin (α-SMA, 1:100, clone 1A4) and desmin (1:100, clone D-33) (both from Dako, Glostrup, Denmark). Immunostaining for α-SMA and desmin was performed using the standard avidin-biotin-peroxidase complex method with an automated immunostainer (Benchmark XT; Ventana Medical System, Tucson, AZ, USA). The signature characteristic of myofibroblasts is an α-SMA-positive and desmin-negative pattern, whereas that of smooth muscle is an α-SMA-positive and desmin-positive pattern.

Takatsuna M., Morohashi S., Yoshizawa T., Hirai H., Haga T., Ota R., Wu Y., Morohashi H., Hakamada K., Terai S, & Kijima H. (2016). Myofibroblasts of the muscle layer stimulate the malignant potential of colorectal cancer. Oncology Reports, 36(3), 1251-1257.

+ Open protocol

+ Expand

Immunohistochemical Panel for Sarcoma Diagnosis

Check if the same lab product or an alternative is used in the 5 most similar protocols

The relevant antibodies and the dilutions used in this study are as follows: BRG1 (Santa Cruz Technology clone B-7, 1:250), CD163 (Ventana clone MRQ-26, undiluted), CD31 (Ventana clone JC70, undiluted), CD34 (Ventana clone QBEnd10, undiluted), CDK4 (Invitrogen, clone DCS-31, 1:200), desmin (Ventana clone DE-R-11, undiluted), EMA (Ventana clone DE-R-11, undiluted), ERG (Ventana clone E29, undiluted), INI1 (BD Bioscience clone BAF47, 1:200), MDM2 (Millipore clone IF2, 1:50), NUT (Cell Signaling Technology, clone C52B1, 1:100), S100 (Cell Marque clone 4C4.9, 1:600), SMA (Cell Marque clone 1A4, undiluted), SOX10 (Biocare clone BC34, 1:50), and YAP1 (Santa Cruz Technology clone 63.7, 1:1000).

Dermawan J.K., DiNapoli S.E., Sukhadia P., Mullaney K.A., Gladdy R., Healey J.H., Agaimy A., Cleven A.H., Suurmeijer A.J., Dickson B.C, & Antonescu C.R. (2023). Malignant Undifferentiated Epithelioid Neoplasms with MAML2 rearrangements: a Clinicopathologic Study of Six Cases Demonstrating a Heterogenous Entity. Genes, chromosomes & cancer, 62(4), 191-201.

+ Open protocol

+ Expand

Immunohistochemistry Panel for Tumor Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

The relevant antibodies and the dilutions used in this study are as follows: ALK D5F3 (Cell Signaling Technology clone D5F3, 1:400), CD163 (Ventana clone SP67, undiluted), CD34 (Ventana clone QBEnd10, undiluted), CDK4 (Invitrogen clone DCS-31, 1:300), MDM2 (Millipore IF2, 1:50), SMA (Cell Marque clone 1A4, undiluted), desmin (Ventana clone DE-R-11, undiluted), S100 (Cell Marque clone 4C4.9, 1:600), GLUT1 (Ventana clone pAb, undiluted), EMA (Ventana DE-R-11, undiluted), INI1 (BD Bioscience clone 25/BAF47, 1:200), BRG1 (Santa Cruz Technology clone B-7, 1:250), MUC4 (Cell Marque clone 8G7, 1:100), and STAT6 (Cell Marque clone EP325, 1:250).

Dermawan J.K., Villafania L., Bale T., Singer S., D’Angelo S.P., Tap W.D, & Antonescu C.R. (2022). TRAF7-mutated Fibromyxoid Spindle Cell Tumors are Associated with an Aggressive Clinical Course and Harbor an Undifferentiated Sarcoma Methylation Signature: A Molecular and Clinicopathologic Study of 3 cases. The American journal of surgical pathology, 47(2), 270-277.

+ Open protocol

+ Expand

Antibody Validation for Spindle Cell Neoplasms

Check if the same lab product or an alternative is used in the 5 most similar protocols

The relevant antibodies and the dilutions used in this study are as follows: pan-cytokeratin (AE1/AE3) (Dako, clone M3515, 1:1600), CD10 (Ventana clone SP67, undiluted), cyclin D1 (Thermo Fisher, clone SP4, 1:200), desmin (Ventana, clone DE-R-11, undiluted), ER (Leica Biosystems, clone 6F11, undiluted), H-caldesmon (Cell Marque, clone E89, undiluted), MSA (Ventana, clone HHF35, undiluted), PDGFR-A (Novus Biochemical, clone 1C10, 1:400), PDGFR-B (Abcam, clone Y92, 1:1000), PR (Leica Biosystems, clone 16, undiluted), S100 (Cell Marque, clone 4C4.9, 1:600), SMA (Cell Marque, clone 1A4, undiluted), and SOX10 (Biocare, clone BC34, 1:50). For clinical validation of PDGFRB and PDGFRA antibodies: PDGFRB was validated on 10 PDGFRB-mutant myofibroma(tosis). PDGFRA was validated on 10 PDGFRA-mutant gastrointestinal stromal tumors (GIST). For negative controls, 10 other spindle cell neoplasms (leiomyoma, schwannoma, desmoid) were used for PDGFRB, and 10 KIT-mutant or wild-type GISTs were used for PDGFRA.

Celik I., Stover C., Botto M., Thiel S., Tzima S., Künkel D., Walport M., Lorenz W, & Schwaeble W. (2001). Role of the Classical Pathway of Complement Activation in Experimentally Induced Polymicrobial Peritonitis. Infection and Immunity, 69(12), 7304-7309.

+ Open protocol

+ Expand

Antibody Dilutions for Immunohistochemistry

Check if the same lab product or an alternative is used in the 5 most similar protocols

The relevant antibodies and the dilutions used in this study are as follows: CD10 (Ventana clone SP67, ready- to-use, Washington, DC, USA), cyclin D1 (Thermo Fisher clone SP4, 1:200, Waltham, MA, USA), ER (Leica Biosystems clone 6F11, ready-to-use, Buffalo Grove, IL, USA), PR (Leica Biosystems, clone 16, ready-to-use), pan-cytokeratin (AE1/AE3) (Dako #M3515, 1:1600, Santa Clara, CA, USA), SMA (Cell Marque clone 4C4.9, ready-to-use, Burlington, MA, USA), desmin (Ventana clone DE-r-11, ready-to-use), H-caldesmon (Cell Marque clone E89, ready-to-use), SOX10 (Biocare clone BC34, 1:50, New York, NY, USA), and S100 (Cell Marque clone 4C4.9, 1:600).

Dermawan J.K., Dashti N., Chiang S., Turashvili G., Dickson B.C., Ellenson L.H., Kirchner M., Stenzinger A., Mechtersheimer G., Agaimy A, & Antonescu C.R. (2022). Expanding the Molecular Spectrum of Gene Fusions in Endometrial Stromal Sarcoma: Novel Subunits of the Chromatin Remodeling Complexes PRC2 and NuA4/TIP60 as Alternative Fusion Partners. Genes, chromosomes & cancer, 62(3), 152-160.

+ Open protocol

+ Expand

Immunohistochemistry of FFPE Tissue

Check if the same lab product or an alternative is used in the 5 most similar protocols

When FFPE material was available, IHC was performed on FFPE tissue sections using a fully automated system (Benchmark ULTRA; Ventana Medical Systems, Tucson, AZ). The following antibodies were used: BAP1 (Santa Cruz, 1:50), Calretinin (Ventana, SP65), Cytokeratin-Pan (DAKO, M3515, 1:1600), CK5/6 (Ventana, 790–4554), Desmin (Ventana, 760–2513), EMA (Ventana, E29), ER (Leica, 6F11), Myogenin (Cell Marque, 760–2832), OCT4 (Cell Marque, 760–4392), PAX8 (Proteintech, 10336-I-AP, 1:100), S100 (Z0311, 1:8000, Dako), Vimentin (Ventana, 790–2917), and WT-1 (Leica, PA0562).

Desmeules P., Joubert P., Zhang L., Al-Ahmadie H.A., Fletcher C.D., Vakiani E., Delair D.F., Rekhtman N., Ladanyi M., Travis W.D, & Antonescu C.R. (2017). A Subset of Malignant Mesotheliomas in Young Adults are Associated with Recurrent EWSR1/FUS-ATF1 Fusions. The American journal of surgical pathology, 41(7), 980-988.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!